Contribute Try STAT+ Today

generic drugs

Most Read

prescription drug pricing/NH

Politics By Lev Facher

A court struck down a ban on pharma ‘price gouging.’ One state wants to revive it — and others could follow

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Feds may soon charge generic drug makers for price fixing

FDA Campus

Pharmalot By Ed Silverman

Generic drug makers challenge FDA plan to withdraw their ADHD pills

Pills and Money

First Opinion By Farasat A.S. Bokhari

Clinton’s proposed ban on pay-for-delay deals would do little to lower drug prices

Pharmalot By Ed Silverman

Feds probe drug maker for prices of generic dermatology meds

Pharmalot By Ed Silverman

Drug maker loses appeal of antitrust pay-to-delay case in Europe

EpiPen

Pharmalot By Ed Silverman

How Mylan tried to keep Teva from selling a generic EpiPen

EpiPen

Business By Stephanie Simon

Mylan to launch generic version of EpiPen, at half the cost

All Coverage

Pharmalot By Ed Silverman

Teva, one of the biggest generic makers, joins the brand-name club

Injectable drugs

Pharmalot By Ed Silverman

FDA narrowly defines the ability of compounders to make approved medicines

advertisement

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Was the FDA commissioner paid by drug makers last year?

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Endo may sell assets as reliance on price hikes wanes

Pharmalot By Ed Silverman

India makes it easier to buy its generic drug makers, but will anyone bite?

FDA Securities Fraud

Pharmalot By Ed Silverman

Former FDA official charged with securities fraud for tipping off hedge fund

Turing Pharma

Pharmalot By Ed Silverman

Lawmakers look to prevent drug makers from thwarting generic competition

Pharmalot By Ed Silverman

India’s new patent policy spurs debate over implications for pharma

FDA

Pharmalot By Ed Silverman

FDA again delays rule to allow generic drug makers to change labels

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Walmart and McKesson team up to buy generic drugs

Pharmalot By Ed Silverman

What generics? Americans spent an extra $73b for brand-name meds

Generic medication

The Pharmalot View By Ed Silverman

Generic drug labels don’t always list known side effects. It’s time to change that

Glaxo Smith Kline

Pharmalot By Ed Silverman

Glaxo, other drug makers appeal UK fines for pay-to-delay deals

FDA Headquarters

Pharmalot By Ed Silverman

FDA warns another Indian drug maker on serious quality control lapses

Pharmalot By Ed Silverman

Two drug makers complain India is thwarting licenses for selling generics

FDA Campus

Pharmalot By Ed Silverman

FDA proposes biosimilar labeling that favors generic drug makers

FDA Headquarters

Pharmalot By Ed Silverman

FDA proposes guidelines for generic abuse-deterrent opioids